Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jid.2024.05.037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tans, Bans, and Sedans: How Distance from Tanning Beds May Save Lives.
J Invest Dermatol
December 2024
Harvard School of Public Health, Social and Behavioral Sciences, Boston, Massachusetts, USA. Electronic address:
Meta-analysis and cost-effectiveness analysis of intranasal corticosteroid treatment in allergic rhinitis with ocular symptoms.
Asian Pac J Allergy Immunol
December 2023
GlaxoSmithKline Limited, Singapore.
Background: Intranasal corticosteroid (INCS) has a beneficial effect on ocular symptoms in allergic rhinitis (AR). To our knowledge, the cost-effectiveness of available INCS for AR with ocular symptoms is yet to be demonstrated.
Objective: To evaluate the cost-effectiveness of INCSs including Budesonide (BANS), Mometasone furoate (MFNS), Triamcinolone (TANS), and Fluticasone furoate (FFNS) on ocular symptoms associated with AR in the Thai context.
Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost.
Am J Rhinol
March 2007
ENT of Georgia, Riverdale, Georgia, USA.
Background: The aim of this review was to compare the efficacy, safety, patient preference, and cost-effectiveness of once-daily budesonide aqueous nasal spray (BANS), fluticasone propionate nasal spray (FPNS), mometasone furoate nasal spray (MFNS), and triamcinolone aqueous nasal spray (TANS) for treatment of allergic rhinitis (AR) in adult patients.
Methods: A MEDLINE search (1966 to January 2004) was conducted to identify potentially relevant English language articles. Pertinent abstracts from recent allergy society meetings were identified also.
Cost efficiency of intranasal corticosteroid prescribing patterns in the management of allergic rhinitis.
J Manag Care Pharm
January 2004
Rxperts, Irvine, CA 92618,
Background: Effective treatment of seasonal or perennial allergic rhinitis often requires use of topical intranasal corticosteroids (INSs). Despite differences in recommended starting dosages, the 4 leading INSs by market share are packaged in bottles containing 120 metered-dose sprays.
Objective: To determine the relative prescribed dosages of the leading INSs and compare economic differences resulting from these prescribing behaviors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!